Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors (SAGUSE)

March 27, 2026 updated by: Dr Rey-Millet Quentin, University Hospital, Geneva

Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists

Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach.

This is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days.

To recruit the necessary number of participants, approximately 1.5 years will be needed.

This project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project.

The project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and/or cereals and/or proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam.

At 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

38

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
    • Canton of Geneva
      • Geneva, Canton of Geneva, Switzerland, 1211
        • Recruiting
        • Hôpitaux Universitaires de Genève
        • Contact:
        • Principal Investigator:
          • Rey-Millet RMQuentin Quentin, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Diabetic patients treated by GLP-1 analog

Description

Inclusion Criteria:

  • Female/ Male of 18 years old or more
  • With Type 2 Diabetes
  • Treated with GLP 1 analog for more than 3 months
  • Signed consent
  • ASA between I and IV

Exclusion Criteria:

  • Insuline treatment
  • Gastro intestinal motility disorders
  • Past gastric surgery
  • Hiatal hernia
  • Recent trauma
  • Inability to be lay down for the exam
  • Inability to follow the instructions for the exam (language, dementia)
  • BMI > 40
  • Inability to stop smoking 12h before the measures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Diabetic patients under GLP-1 receptors agonists

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A safe gastric volume for anesthesia in diabetic patients treated with GLP-1 analog after a 6 hours fasting period 7 day after the last injection.
Time Frame: 1 week
Our primary objective is to show that after a fasting period of 6 hours, seven days after the last injection of GLP-1, gastric volume of diabetic patients is safe for anaesthesia. Our hypothesis is that seven days after the last injection of GLP-1, and after a 6h fasting period, the mean gastric volume of treated patients will be lower than 1.5 ml/kg, corresponding to the most accepted volume threshold of an at risk (full) stomach
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Geneva

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

March 21, 2026

First Submitted That Met QC Criteria

March 27, 2026

First Posted (Actual)

April 1, 2026

Study Record Updates

Last Update Posted (Actual)

April 1, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-01341

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Regurgitation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe